Glucocorticoid receptor β induces hepatic steatosis by augmenting inflammation and inhibition of the Peroxisome Proliferator-activated Receptor (PPAR) α

Journal of Biological Chemistry

Volumn 291, Issue 50, 2016, Pages 25776-25788

  Marino, Joseph S ^a   Stechschulte, Lance A ^b   Stec, David E ^c   Nestor Kalinoski, Andrea ^b   Coleman, Sydni ^d   Hinds, Terry D ^b  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; CELL CULTURE; CHEMICAL ACTIVATION; HORMONES; MACROPHAGES; NITRIC OXIDE; PATHOLOGY;

FIBROBLAST GROWTH FACTOR; GLUCOCORTICOID RECEPTOR; GLYCOGEN SYNTHASE KINASE; HEPATIC GLUCONEOGENESIS; INDUCIBLE NITRIC OXIDE SYNTHASE; LIGAND BINDING DOMAIN; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

MAMMALS;

FIBROBLAST GROWTH FACTOR 21; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; FIBROBLAST GROWTH FACTOR; GLUCOCORTICOID RECEPTOR; GSK3B PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID OXIDATION; FATTY LIVER; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INFLAMMATION; LIPID STORAGE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; AGONISTS; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE;

ANIMALS; FATTY LIVER; FIBROBLAST GROWTH FACTORS; GLUCOCORTICOIDS; GLYCOGEN SYNTHASE KINASE 3 BETA; INFLAMMATION; MALE; MICE; NF-KAPPA B; PPAR ALPHA; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85002806659     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.752311     Document Type: Article

References (67)

1. Day, C. P., and James, O. F. (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114, 842-845
2. Paschos, P., and Paletas, K. (2009) Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 13, 9-19
3. John, K., Marino, J. S., Sanchez, E. R., and Hinds, T. D., Jr. (2016) The glucocorticoid receptor: cause of or cure for obesity? Am. J. Physiol. Endocrinol. Metab. 310, E249-257
4. Dunderski, J., and Matic, G. (2009) Glucocorticoid receptor in health and disease. J. Med. Biochem. 28, 248-261
5. McBeth, L., Nwaneri, A. C., Grabnar, M., Demeter, J., Nestor-Kalinoski, A., and Hinds, T. D., Jr. (2016) Glucocorticoid receptor β increases migration of human bladder cancer cells. Oncotarget 7, 27313-27324
6. Wang, Y., Romigh, T., He, X., Tan, M. H., Orloff, M. S., Silverman, R. H., Heston, W. D., and Eng, C. (2011) Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 30, 4327-4338
7. Hinds, T. D., Peck, B., Shek, E., Stroup, S., Hinson, J., Arthur, S., and Marino, J. S. (2016) Overexpression of glucocorticoid receptor β enhances myogenesis and reduces catabolic gene expression. Int. J. Mol. Sci. 17, 232
8. Hinds, T. D., Jr, Ramakrishnan, S., Cash, H. A., Stechschulte, L. A., Heinrich, G., Najjar, S. M., and Sanchez, E. R. (2010) Discovery of glucocorticoid receptor-β in mice with a role in metabolism. Mol. Endocrinol. 24, 1715-1727
9. Stechschulte, L. A., Wuescher, L., Marino, J. S., Hill, J. W., Eng, C., and Hinds, T. D., Jr. (2014) Glucocorticoid receptor beta stimulates Akt1 growth pathway by attenuation of PTEN. J. Biol. Chem. 289, 17885-17894
10. DuBois, D. C., Sukumaran, S., Jusko, W. J., and Almon, R. R. (2013) Evidence for a glucocorticoid receptor β splice variant in the rat and its physiological regulation in liver. Steroids 78, 312-320
11. He, B., Cruz-Topete, D., Oakley, R. H., Xiao, X., and Cidlowski, J. A. (2015) Human glucocorticoid receptor β (hGRβ) regulates gluconeogenesis and inflammation in mouse liver. Mol. Cell. Biol. 36, 714-730
12. Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., Barquissau, V., Régnier, M., Lukowicz, C., Benhamed, F., Iroz, A., Bertrand-Michel, J., Al Saati, T., Cano, P., Mselli-Lakhal, L., et al. (2016) Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 65, 1202-1214
13. Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., and Maratos-Flier, E. (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59, 2781-2789
14. Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela-Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez-Chantar, M. L., and Maratos-Flier, E. (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139, 456-463
15. Chau, M. D., Gao, J., Yang, Q., Wu, Z., and Gromada, J. (2010) Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1α pathway. Proc. Natl. Acad. Sci. U.S.A. 107, 12553-12558
16. Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y. S., Lindberg, R. A., Chen, J. L., Jung, D. Y., Zhang, Z., Ko, H. J., Kim, J. K., and Véniant, M. M. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259
17. Potthoff, M. J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B. N., Mangelsdorf, D. J., Kliewer, S. A., and Burgess, S. C. (2009) FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. U.S.A. 106, 10853-10858
18. Berglund, E. D., Li, C. Y., Bina, H. A., Lynes, S. E., Michael, M. D., Shanafelt, A. B., Kharitonenkov, A., and Wasserman, D. H. (2009) Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150, 4084-4093
19. Hinds, T. D., Jr., Sodhi, K., Meadows, C., Fedorova, L., Puri, N., Kim, D. H., Peterson, S. J., Shapiro, J., Abraham, N. G., and Kappas, A. (2014) Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. Obesity 22, 705-712
20. Goecke, A., and Guerrero, J. (2006) Glucocorticoid receptor beta in acute and chronic inflammatory conditions: clinical implications. Immunobiology 211, 85-96
21. Hinds, T. D., Jr, Stechschulte, L. A., Cash, H. A., Whisler, D., Banerjee, A., Yong, W., Khuder, S. S., Kaw, M. K., Shou, W., Najjar, S. M., and Sanchez, E. R. (2011) Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome proliferator-activated receptor-γ (PPARγ). J. Biol. Chem. 286, 42911-42922
22. Sharma, M., Mitnala, S., Vishnubhotla, R. K., Mukherjee, R., Reddy, D. N., and Rao, P. N. (2015) The riddle of nonalcoholic fatty liver disease: progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. J. Clin. Exp. Hepatol. 5, 147-158
23. Bozzetto, L., Annuzzi, G., Ragucci, M., Di Donato, O., Della Pepa, G., Della Corte, G., Griffo, E., Anniballi, G., Giacco, A., Mancini, M., and Rivellese, A. A. (2016) Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk. Nutr. Metab. Cardiovasc. Dis. 26, 623-629
24. Robert, O., Boujedidi, H., Bigorgne, A., Ferrere, G., Voican, C. S., Vettorazzi, S., Tuckermann, J. P., Bouchet-Delbos, L., Tran, T., Hemon, P., Puchois, V., Dagher, I., Douard, R., Gaudin, F., Gary-Gouy, H., et al. (2016) Decreased expression of the glucocorticoid receptor-GILZ pathway in Kupffer cells promotes liver inflammation in obese mice. J. Hepatol. 64, 916-924
25. Shulman, G. I. (2014) Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 371, 2237-2238
26. Samuel, V. T., and Shulman, G. I. (2016) The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Investig. 126, 12-22
27. Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., 3rd, Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., and Birnbaum, M. J. (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292, 1728-1731
28. Tipoe, G. L., Ho, C. T., Liong, E. C., Leung, T. M., Lau, T. Y., Fung, M. L., and Nanji, A. A. (2009) Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD). Histol. Histopathol. 24, 1161-1169
29. Vasudevan, K. M., Gurumurthy, S., and Rangnekar, V. M. (2004) Suppression of PTEN expression by NF-κB prevents apoptosis. Mol. Cell. Biol. 24, 1007-1021
30. Komatsu, M., Kimura, T., Yazaki, M., Tanaka, N., Yang, Y., Nakajima, T., Horiuchi, A., Fang, Z. Z., Joshita, S., Matsumoto, A., Umemura, T., Tanaka, E., Gonzalez, F. J., Ikeda, S., and Aoyama, T. (2015) Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARα. Biochim. Biophys. Acta 1852, 473-481
31. Francque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M. R., Van Hul, W., Mertens, I., Hubens, G., Van Marck, E., Michielsen, P., Van Gaal, L., and Staels, B. (2015) PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J. Hepatol. 63, 164-173
32. Kimura, R., Takahashi, N., Murota, K., Yamada, Y., Niiya, S., Kanzaki, N., Murakami, Y., Moriyama, T., Goto, T., and Kawada, T. (2011) Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes. Biochem. Biophys. Res. Commun. 410, 1-6
33. Abdelmegeed, M. A., Yoo, S. H., Henderson, L. E., Gonzalez, F. J., Woodcroft, K. J., and Song, B. J. (2011) PPARα expression protects male mice from high fat-induced nonalcoholic fatty liver. J. Nutr. 141, 603-610
34. Stec, D. E., John, K., Trabbic, C. J., Luniwal, A., Hankins, M. W., Baum, J., and Hinds, T. D. (2016) Bilirubin binding to PPARα inhibits lipid accumulation. PloS One 11, e0153427
35. Ramakrishnan, S. K., Khuder, S. S., Al-Share, Q. Y., Russo, L., Abdallah, S. L., Patel, P. R., Heinrich, G., Muturi, H. T., Mopidevi, B. R., Oyarce, A. M., Shah, Y. M., Sanchez, E. R., and Najjar, S. M. (2016) PPARα (peroxisome proliferator-activated receptor α) activation reduces hepatic CEACAM1 protein expression to regulate fatty acid oxidation during fasting-refeeding transition. J. Biol. Chem. 291, 8121-8129
36. Ge, X., Chen, C., Hui, X., Wang, Y., Lam, K. S., and Xu, A. (2011) Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J. Biol. Chem. 286, 34533-34541
37. Badman, M. K., Koester, A., Flier, J. S., Kharitonenkov, A., and Maratos-Flier, E. (2009) Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150, 4931-4940
38. Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., and Kharitonenkov, A. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149, 6018-6027
39. Arner, P., Pettersson, A., Mitchell, P. J., Dunbar, J. D., Kharitonenkov, A., and Rydén, M. (2008) FGF21 attenuates lipolysis in human adipocytes: a possible link to improved insulin sensitivity. FEBS Lett. 582, 1725-1730
40. Markan, K. R., Naber, M. C., Ameka, M. K., Anderegg, M. D., Mangelsdorf, D. J., Kliewer, S. A., Mohammadi, M., and Potthoff, M. J. (2014) Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63, 4057-4063
41. Patel, R., Bookout, A. L., Magomedova, L., Owen, B. M., Consiglio, G. P., Shimizu, M., Zhang, Y., Mangelsdorf, D. J., Kliewer, S. A., and Cummins, C. L. (2015) Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. Mol. Endocrinol. 29, 213-223
42. Uysal, K. T., Wiesbrock, S. M., Marino, M. W., and Hotamisligil, G. S. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389, 610-614
43. Zhao, L., Zhong, S., Qu, H., Xie, Y., Cao, Z., Li, Q., Yang, P., Varghese, Z., Moorhead, J. F., Chen, Y., and Ruan, X. Z. (2015) Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice. Sci. Rep. 5, 10222
44. Wuescher, L., Angevine, K., Patel, P. R., and Mensah-Osman, E. (2012) Menin liver-specific hemizygous mice challenged with high fat diet show increased weight gain and markers of metabolic impairment. Nutr. Diabetes 2, e34
45. Warrier, M., Hinds, T. D., Jr., Ledford, K. J., Cash, H. A., Patel, P. R., Bowman, T. A., Stechschulte, L. A., Yong, W., Shou, W., Najjar, S. M., and Sanchez, E. R. (2010) Susceptibility to diet-induced hepatic steatosis and glucocorticoid resistance in FK506-binding protein 52-deficient mice. Endocrinology 151, 3225-3236
46. Meli, R., Mattace Raso, G., and Calignano, A. (2014) Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front. Immunol. 5, 177
47. Vazquez-Tello, A., Halwani, R., Hamid, Q., and Al-Muhsen, S. (2013) Glucocorticoid receptor-β up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells. J. Clin. Immunol. 33, 466-478
48. Christodoulopoulos, P., Leung, D. Y., Elliott, M. W., Hogg, J. C., Muro, S., Toda, M., Laberge, S., and Hamid, Q. A. (2000) Increased number of glucocorticoid receptor-β-expressing cells in the airways in fatal asthma. J. Allergy Clin. Immunol. 106, 479-484
49. Webster, J. C., Oakley, R. H., Jewell, C. M., and Cidlowski, J. A. (2001) Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative β isoform: a mechanism for the generation of glucocorticoid resistance. Proc. Natl. Acad. Sci. U.S.A. 98, 6865-6870
50. Goyal, R., Faizy, A. F., Siddiqui, S. S., and Singhai, M. (2012) Evaluation of TNF-α and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin effects. N. Am. J. Med. Sci. 4, 180-184
51. Moon, Y. S., Kim, D. H., and Song, D. K. (2004) Serum tumor necrosis factor-α levels and components of the metabolic syndrome in obese adolescents. Metabolism 53, 863-867
52. Romeo, G. R., Lee, J., and Shoelson, S. E. (2012) Metabolic syndrome, insulin resistance, and roles of inflammation: mechanisms and therapeutic targets. Arterioscler. Thromb. Vasc. Biol. 32, 1771-1776
53. Shoelson, S. E., Herrero, L., and Naaz, A. (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169-2180
54. Shoelson, S. E., Lee, J., and Goldfine, A. B. (2006) Inflammation and insulin resistance. J. Clin. Investig. 116, 1793-1801
55. Smith, B. W., and Adams, L. A. (2011) Non-alcoholic fatty liver disease. Crit. Rev. Clin. Lab. Sci. 48, 97-113
56. Sato, W., Horie, Y., Kataoka, E., Ohshima, S., Dohmen, T., Iizuka, M., Sasaki, J., Sasaki, T., Hamada, K., Kishimoto, H., Suzuki, A., and Watanabe, S. (2006) Hepatic gene expression in hepatocyte-specific Pten deficient mice showing steatohepatitis without ethanol challenge. Hepatol. Res. 34, 256-265
57. Rando, G., Tan, C. K., Khaled, N., Montagner, A., Leuenberger, N., Bertrand-Michel, J., Paramalingam, E., Guillou, H., and Wahli, W. (2016) Glucocorticoid receptor-PPARα axis in fetal mouse liver prepares neonates for milk lipid catabolism. Elife 5, e11853
58. Mandard, S., Stienstra, R., Escher, P., Tan, N. S., Kim, I., Gonzalez, F. J., Wahli, W., Desvergne, B., Müller, M., and Kersten, S. (2007) Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors. Cell. Mol. Life Sci. 64, 1145-1157
59. O'Brien, K. A., Gartner, T. K., Hay, N., and Du, X. (2012) ADP-stimulated activation of Akt during integrin outside-in signaling promotes platelet spreading by inhibiting glycogen synthase kinase-3β. Arterioscler. thromb. Vasc. Biol. 32, 2232-2240
60. Nandan, D., Camargo de Oliveira, C., Moeenrezakhanlou, A., Lopez, M., Silverman, J. M., Subek, J., and Reiner, N. E. (2012) Myeloid cell IL-10 production in response to leishmania involves inactivation of glycogen synthase kinase-3β downstream of phosphatidylinositol-3 kinase. J. Immunol. 188, 367-378
61. Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., and Maratos-Flier, E. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5, 426-437
62. Samms, R. J., Cheng, C. C., Kharitonenkov, A., Gimeno, R. E., and Adams, A. C. (2016) Overexpression of β-klotho in adipose tissue sensitizes male mice to endogenous FGF21 and provides protection from diet-induced obesity. Endocrinology 157, 1467-1480
63. Camporez, J. P., Asrih, M., Zhang, D., Kahn, M., Samuel, V. T., Jurczak, M. J., and Jornayvaz, F. R. (2015) Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21. J. Endocrinol. 226, 207-217
64. Nwaneri, A. C., McBeth, L., and Hinds, T. D., Jr. (2016) Sweet-P inhibition of glucocorticoid receptor β as a potential cancer therapy. Cancer Cell Microenviron. 3, e1362
65. Lee, S. J., Heinrich, G., Fedorova, L., Al-Share, Q. Y., Ledford, K. J., Fernstrom, M. A., McInerney, M. F., Erickson, S. K., Gatto-Weis, C., and Najjar, S. M. (2008) Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice. Gastroenterology 135, 2084-2095
66. Luo, J., Deng, Z. L., Luo, X., Tang, N., Song, W. X., Chen, J., Sharff, K. A., Luu, H. H., Haydon, R. C., Kinzler, K. W., Vogelstein, B., and He, T. C. (2007) A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat. Protoc. 2, 1236-1247
67. Stechschulte, L. A., Qiu, B., Warrier, M., Hinds, T. D., Jr, Zhang, M., Gu, H., Xu, Y., Khuder, S. S., Russo, L., Najjar, S. M., Lecka-Czernik, B., Yong, W., and Sanchez, E. R. (2016) FKBP51 null mice are resistant to diet-induced obesity and the PPARγ agonist rosiglitazone. Endocrinology 157, 3888-3900